Inveready has invested in Cuantum Medical Cosmetics, SL. Ramon Bacardit (previously executive at Henkel) and Ferran Pujol (former R&D director at Spanish pharma Almirall) founded Cuantum in November 2015 to develop and market medical adhesives based on cyanoacrylates. Cuantum’s patented process allows the synthesis of high purity cyanoacrylates and a variety of new formulations at a competitive cost. Cuantum has a powerful commercial structure in Latin America and Asia.
The 1,6 Milion euro round was raised from the founders, private investors, and Inveready. The start-up round will allow Cuantum to deploy its commercial strategy at two levels: in the Business-to-Business market, Cuantum will commercialize cyanoacrylate monomers and formulations. In the Business-to-Consumer market, Cuantum will launch up to 10 new products in the next two years for the veterinary, cosmetic and medical (OTC and Hospital channels) sectors. The worldwide market for high strength medical adhesives was worth USD650 Million in 2010 with CAGR of 15%. Dermabond® (Johnson and Johnson) is one of the market leaders.
"What attracted us to Cuantum, was the proven track-record of these serial entrepreneurs that have already shown an exceptional ability to generate high-growth businesses in mature markets in record time" says Sara Secall, Investment Director at Inveready ".
Inveready is one of the top seed Venture Capital investors operating in Spain since 2008. With five Venture Funds and 70 million euros under management, Inveready invests in high growth technology companies. Its current portfolio of over 60 companies includes telecom, internet, IT, and biotech investments
cloud technology axon
Palex Medical has announced the execution of a put option agreement fo...
